Caris Life Sciences Inc - Class A CAI Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$25.23 down $0.80, 3.07% at close Nov 6
Last close · Previous close $26.03
- Market cap
- At the Nov 6 close
- P/E ratio
- 15.20On last 12 months’ EPS
- Diluted EPS
- $1.66Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$25.23down $0.80, 3.07%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$26.03Nov 5
- Volume10.24MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.90MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $14.19 to $36.50; now $25.23
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CAI beat the S&P 500 in 1 of 4 periods.
| Period | CAI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CAI: down 8.1% S&P 500: down 5.6% | CAI trailed the S&P 500 by 2.5 percentage points Trailed |
| 3M | CAI: up 26.2% S&P 500: down 4.1% | CAI beat the S&P 500 by 30.3 percentage points Beat |
| YTD | CAI: down 6.5% S&P 500: up 8.7% | CAI trailed the S&P 500 by 15.2 percentage points Trailed |
| 1Y | CAI: up 2.5% S&P 500: up 10.9% | CAI trailed the S&P 500 by 8.4 percentage points Trailed |
$10,000 invested in CAI a year ago (Nov 6, 2025) would be worth about $10,252 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
CAI beat the S&P 500 in 1 of 4 periods.
| Period | CAI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CAI: down 8.1% S&P 500: down 5.6% | CAI trailed the S&P 500 by 2.5 percentage points Trailed |
| 3M | CAI: up 26.2% S&P 500: down 4.3% | CAI beat the S&P 500 by 30.5 percentage points Beat |
| YTD | CAI: down 6.5% S&P 500: up 7.8% | CAI trailed the S&P 500 by 14.3 percentage points Trailed |
| 1Y | CAI: up 2.5% S&P 500: up 9.7% | CAI trailed the S&P 500 by 7.2 percentage points Trailed |
$10,000 invested in CAI a year ago (Nov 6, 2025) would be worth about $10,252 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$39.30
Closing high on . Now 35.8% below that record.
Split-adjusted daily closes since Jun 18, 2025.
Stock splits
CAI hasn’t split since its price history begins in 2025.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.05Bup 61.5%
- Net income
- $96.06M
- Diluted EPS
- $1.66
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $129.92M | −$36.95M | −$1.74 |
| Q1 FY25 (Mar 31, 2025) | $120.92M | −$102.58M | −$3.57 |
| Q2 FY25 (Jun 30, 2025) | $181.40M | −$71.79M | −$7.97 |
| Q3 FY25 (Sep 30, 2025) | $216.83M | $24.33M | $0.08 |
| Q4 FY25 (Dec 31, 2025) | $292.89M | $81.96M | $1.61 |
| Q1 FY26 (Mar 31, 2026) | $216.17M | −$510.00K | $0.00 |
| Q2 FY26 (Jun 30, 2026) | $263.71M | −$637.00K | $0.00 |
| Q3 FY26 (Sep 30, 2026) | $275.36M | $15.25M | $0.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY23 (Dec 31, 2023) | $306.13M | −$341.42M | −$13.24 |
| FY24 (Dec 31, 2024) | $412.26M | −$281.89M | −$10.66 |
| FY25 (Dec 31, 2025) | $812.03M | −$68.09M | −$3.22 |
Margins
- Gross 69.1%
- Operating 10.8%
- Net 9.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $28.91MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$83.89MLast 12 months
- Capital spending$54.98MLast 12 months
- 2.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.39MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $767.38MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$393.27MAs of Sep 30, 2026
- Net cash$374.11MAs of Sep 30, 2026
- 6.71As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.61As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 16.0%Last 12 months
Over the last 12 months, Caris Life Sciences’s net income was 16.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 8.0%Last 12 months
Over the last 12 months, Caris Life Sciences’s net income was 8.0% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Caris Life Sciences Inc - Class A
Caris Life Sciences Inc - Class A
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CAI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CAI stock FAQ
What is CAI stock’s price today?
Caris Life Sciences (CAI) traded at $25.23 at the close on , down $0.80 (3.07%) from the previous close of $26.03. Over the past 52 weeks it has traded between $14.19 and $36.50.
What is CAI’s P/E ratio?
CAI trades at 15.2 times its diluted earnings over the four quarters to ($1.66 per share), at the close. (How the P/E ratio works.)
How much revenue does Caris Life Sciences make?
Caris Life Sciences reported $1.0 billion of revenue over the four quarters to , up 61.5% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $275.4 million, up 27.0% from a year earlier.
Is Caris Life Sciences profitable?
Yes. Caris Life Sciences earned $96.1 million of net income over the four quarters to , a net margin of 9.2%, and its operating margin was 10.8% (what margins tell you).
What are CAI’s earnings per share?
CAI’s diluted earnings per share were $1.66 over the four quarters to , compared with −$13.20 in the twelve months before. The latest quarter (Q3 FY26) brought $0.05 per share, against $0.08 a year earlier (how EPS works).
Does CAI pay a dividend?
Caris Life Sciences hasn’t paid a dividend in the last twelve months.
What is CAI’s 52-week high and low?
Over the past 52 weeks CAI has traded as low as $14.19 and as high as $36.50. At $25.23 at the close on , it is 30.9% below that high and 77.8% above the low.
What is CAI’s all-time high?
CAI’s highest closing price was $39.30 on , adjusted for stock splits. At $25.23 at the close on , it is 35.8% below that record.
Has CAI stock ever split?
No. CAI hasn’t split since its price history begins in 2025.
How has CAI stock performed?
Including dividends and measured to the close on , CAI has returned −6.5% so far this year and +2.5% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is Caris Life Sciences in?
Caris Life Sciences is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
What exchange does CAI trade on?
Caris Life Sciences trades on the Nasdaq under the ticker symbol CAI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.